Bristol Myers Squibb (BMS) announced a definitive agreement in which BMS will acquire Orbital Therapeutics along with its ...

Bristol Myers Squibb has agreed to acquire Orbital Therapeutics, a privately held biotechnology company pioneering a new ...

The deal will bolster BMS's cell therapy efforts by adding Orbital's lead program in autoimmune diseases and RNA platform to its portfolio.

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases Transaction further ...

The magnet-free inductive position sensor ICs are customisable for a range of coil designs compatible with a wide range of industrial applications ...